Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Provides AI platform for homebuilding design, estimating and construction
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Builds systems software for AI applications, powering inference and multi-model strategies
Provides a unified IT operations platform for simplifying work
Provides AI-native data infrastructure for physical AI systems
Pitching Wellington Management? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room